# Tecarfarin Anti-Coagulation Trial (TACT)

Study · id `cardio:ct-nct02522221` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02522221](<https://clinicaltrials.gov/study/NCT02522221>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02522221

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 1000 participants.

## Technical summary

Registry record NCT02522221. Randomized; no masking; primary purpose treatment. Start 2018-06-01 (anticipated); primary completion 2019-03-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 1000 participants (planned count; ClinicalTrials.gov record NCT02522221, source copy `cardio:ctgov-nct02522221-2018-01-25`, retrieved 2026-10-26)
- Planned start: 2018-06-01 (anticipated) (ClinicalTrials.gov record NCT02522221, source copy `cardio:ctgov-nct02522221-2018-01-25`, retrieved 2026-10-26)
- Primary completion: 2019-03-30 (anticipated) (ClinicalTrials.gov record NCT02522221, source copy `cardio:ctgov-nct02522221-2018-01-25`, retrieved 2026-10-26)
- Completion: 2019-07-01 (anticipated) (ClinicalTrials.gov record NCT02522221, source copy `cardio:ctgov-nct02522221-2018-01-25`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02522221-2018-01-25`, retrieved 2026-10-26)

## The registry's words

- Brief title: Tecarfarin Anti-Coagulation Trial (TACT)
- Acronym: TACT
- Condition: Thromboembolism
- Condition: Thrombosis
- Intervention (Drug): Warfarin
- Intervention (Drug): tecarfarin
- Lead sponsor: Espero Biopharma
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry intervention name matches this record: Warfarin (`core:warfarin`)

## Provenance

Content hash: 1d19308fee89ea592d39bca014b518787897b52711dee05bb759580a6f181757
Last substantive edit: 2026-10-30
Evidence last checked: Not recorded
